EAM Investors’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

EAM Investors’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-55,532	Closed	-$2.72M	–	349
2020 Q1	$2.72M	Buy	55,532 +6,859	+14%	+$349K	0.85%	17
2019 Q4	$2.79M	Buy	48,673 +15,760	+48%	+$780K	0.61%	42
2019 Q3	$1.18M	Sell	32,913 -38,548	-54%	-$1.51M	0.31%	157
2019 Q2	$2.22M	Buy	+71,461	New	+$1.94M	0.54%	50

Other funds holding EIDX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

EAM Investors's EIDX Position: Q2 2020 in Review

EAM Investors sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q2 2020, closing a stake of 55,532 shares — an estimated $2.72M sold.

EAM Investors first reported a position in EIDX in Q2 2019 and held it in 4 quarters. The position peaked at $2.79M in Q4 2019. 92 funds tracked by Wall St. Rank hold EIDX as of Q2 2020.

EAM Investors reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
EAM Investors sold 55,532 Eidos Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $2.72M.
EAM Investors first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 4 quarters.
EAM Investors's Eidos Therapeutics, Inc. Common Stock position peaked at $2.79M in Q4 2019.
92 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q2 2020.

Based on EAM Investors's 13F filing for Q2 2020, filed 13 Aug 2020.